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Abstract
Introduction: Known biomarkers of Gaucher-disease activity are platelets, chitotriosidase, angiotensin-converting
enzyme (ACE), tartrate-resistant acid phosphatase (TRAP) and ferritin. The aim of this study was to retrospectively
evaluate the frequency of bone events (BE) and biomarker changes during two periods: diagnosis to first enzyme-
replacement therapy (ERT) and the latter to the closing date.
Methods: BE of 62 treated patients, among the 73-patient cohort followed at Beaujon Hospital, Clichy, France,
were described with Kaplan-Meier curves, and linear-mixed models were used to analyze their biomarker changes
and the influence of several covariates (splenectomy, diagnosis year, genotype, age at diagnosis and sex).
Results: BE occurred before (54 events in 21 patients), but also during, ERT (12 events in 10 patients), with
respective frequencies (95% confidence interval) at 10 years of 22.4% (13.3 to 36.3) and 20.0% (10.2 to 36.9).
Biomarker slope changes before and during ERT differed significantly for platelets (+190/mm
3/year and 7,035/mm
3/
year, respectively; P < 0.0001) and ferritin (+4% and -14%; P < 0.0001). High ferritin levels and low platelet counts at
ERT onset were significantly associated with BE during ERT (P = 0.019 and 0.039, respectively). Covariates
significantly influenced biomarker changes (baseline and/or slope): splenectomy affected platelets (baseline and
changes), TRAP changes and chitotriosidase changes; diagnosis date influenced ACE and TRAP baseline values; and
genotype influenced chitotriosidase baseline and changes.
Conclusions: Platelet counts and ferritin levels and their slope changes at ERT onset seem to predict BE during
treatment. Biomarker baseline values and changes are dependent on several covariables.
Introduction
Gaucher disease (GD), a rare autosomal-recessive disor-
der with an approximate prevalence of 1/75,000 live
births worldwide, is due to the deficiency of a lysosomal
enzyme (glucocerebrosidase, glucosylceramidase or b-
glucosidase acid (EC 3.2.1.45)) [1] or, rarely, its activator
(saposin C) [2,3]. This lysosomal storage disease is char-
acterized by liver and spleen enlargement, and severe
bone complications [1]. Based on the neurological signs,
three clinical phenotypes are recognized: type 1, the
classic form, affects 95% of the patients and is usually
defined by the absence of central nervous system
impairment; types 2 and 3 are rare and severe, due to
neurological involvement [4].
Type 1 GD has bone complications that can alter the
functional prognosis: abnormal bone deformity, such as
widening of the femur metaphysis (Erlenmeyer flask),
osteopenia, osteoporosis, lytic lesions and pathological
and vertebral compression fractures. Bone infarcts are
manifested by acute painful bone crises, and avascular
necroses lead to degenerative arthropathy that may
require replacement by prosthesis [5]. Thrombopenia
and anemia are common. Liver enzymes may be slightly
elevated and cholestasis may be present. GD diagnosis is
confirmed by the detection of low glucocerebrosidase
activity, usually less than 30% of the normal value in
peripheral leukocytes. Genotyping can sometimes pro-
vide prognosis information [6].
Enzyme-replacement therapy (ERT), alglucerase then
imiglucerase, available since 1991, is the reference treat-
ment. Substrate-reduction therapy (miglustat) has been
available since 2002, and is indicated for moderate GD
when ERT is unsuitable. These treatments are extremely
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onset of neurological disorders in type 2 [4,7]. To our
knowledge, no complete analysis of bone complications
occurring under ERT is available. Bone complications
generally decline after two years of ERT [8]. However,
no data are available on the main bone events (BE; avas-
cular necrosis, bone infarcts, pathological fractures)
occurring during ERT.
Several biomarkers (chitotriosidase, ferritin, angioten-
sin-converting enzyme (ACE) and tartrate-resistant acid
phosphatase (TRAP)) are elevated during GD evolution
[9-16]. Their concentrations rise with disease progres-
sion and generally decrease during ERT [17]. At present,
it is not possible to make any formal recommendations
concerning the use of any specific marker for patient
monitoring [18]. Moreover, it is not known if biomarker
levels at diagnosis can predict GD prognosis of treated
and untreated patients, and which patients will respond,
or not, to therapy [19]. Despite the lack of official guide-
lines, ACE, TRAP and chitotriosidase are used to moni-
tor GD follow-up [20].
Several studies on chronic diseases used biomarker
modeling to describe their evolution: human immuno-
deficiency virus infection [21], Parkinson disease [22]
and diabetes mellitus [23]. Concerning GD patients,
most published studies are descriptions of small
cohorts (median number of patients, 29; range, 18 to
48) [9,10,17,19,24,25] and only one study modeled
hemoglobin and platelet levels and splenic volume
under ERT [26].
Therefore, this study was undertaken to analyze BE
frequencies occurring during the periods before and
during ERT in our cohort of GD patients and to model
the progression of their biological marker levels or slope
changes.
Materials and methods
Patients and data collected
The Referral Center for Lysosomal Diseases (RCLD) is
specialized in GD follow-up. A designated French
national GD registry was developed and is maintained
by the RCLD. Although patients are treated and fol-
lowed in hospitals near their homes, they are registered
with the RCLD, which is available to assist their physi-
cians. However, a cohort of patients is followed and
treated on-site in the RCLD. All patients with known
GD entered in the RCLD registry, followed on-site in
the Department of Internal Medicine, Beaujon Hospital
(Clichy, France), and receiving ERT were included. Clin-
ical, biological and radiological data were recorded for
all patients from diagnosis until 1 May 2007, the closing
date. Data were collected retrospectively for two periods:
before and during ERT.
Written consent was obtained from each patient. The
local Institutional Review Board of Northern Paris Hos-
pitals, Paris-Diderot University, AP-HP (Ethics Commit-
tee) reviewed and approved the research project.
A standardized case-report form was used to collect
the following information at each visit: initial data (age,
sex, history related or unrelated to GD, initial symptoms
and their year of onset, test confirming the diagnosis,
phenotype, genotype, unknown genetic mutation); clini-
cal information during the first consultation, at diagno-
sis and throughout follow-up; organomegaly (liver and/
or spleen), usually measured using diagnostic ultrasono-
graphy (largest diameter); biological findings initially
and throughout follow-up. Bone findings (X-rays, mag-
netic resonance imaging and, for some patients, scinti-
graphy and dual-energy X-ray absorptiometry) were
recorded during follow-up, with identification of inter-
current events, particularly bone complications.
BE were defined as clinical events using the bone indi-
cations for treatment recommended by the French
National Health Authority [27]: avascular necrosis of an
epiphysis, bone infarct, pathological and/or vertebral
compression fracture(s). Each BE had a clinical manifes-
tation and radiological confirmation. Bone pain alone
was not considered a BE without radiological
confirmation.
Monitoring of GD-specific ERT and combined thera-
pies (analgesics and bisphosphonates) were noted.
GD diagnosis was confirmed by low glucocerebrosi-
dase activity in leukocytes [28] for all patients. Chito-
triosidase activity in plasma samples was determined
using the fluorescent substrate 4-methyl umbeliferyl b-
d-N,N′,N′′-(MU)-triacylchitotriose [9]; ACE, TRAP, ferri-
tin and other measurements were made in the appropri-
ate local laboratories. Because this study was
retrospective, some data were missing, particularly at
the beginning of follow-up (during the diagnosis phase).
When missing, the baseline value at ERT onset was
replaced with the last known value during the two pre-
vious years. When the chitotriosidase concentration was
undetectable (patients with homozygous chitotriosidase-
gene deficiency), this biomarker was not retested [29].
Statistical analysis
All statistical analyses were performed with SAS soft-
ware (version 9.1; SAS Institute Inc, Cary, North Caro-
lina, USA). The significance level was set at P < 0.05.
First, we described BE frequency using Kaplan-Meier
probability-of-BE curves to determine the time to the
first BE for treated patients between diagnosis and their
first treatment (before ERT), and between first ERT and
the closing date (during ERT). Only the first BE occur-
ring during each period was considered. Data were
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ERT for the first analysis and until the closing date for
the second analysis. The LIFETEST procedure was used.
Second, we analyzed the changes of the five GD bio-
markers (platelets, chitotriosidase, ferritin, ECA, TRAP)
using linear-mixed models for repeated measures with
the MIXED procedure. Because of their minimal varia-
tions during ERT, hemoglobin levels were not included
in this model. The MIXED procedure is a generalization
of a standard linear regression, which allows modeling
of the parameter changes for each individual over time
and takes into account the intrasubject association. Bio-
marker changes over time could have one of two shapes:
either a linear increase or an exponential decrease. For
the latter, logarithmic transformation was used in the
model. Models of platelet changes used only the counts
of nonsplenectomized patients. Two categories were cre-
ated and analyzed: before and during ERT, regardless of
the dose, with analysis of patients receiving full-dose
ERT as a subcategory. Before-and-during ERT slopes
were compared using the Wald test.
Third, we analyzed the effects of five covariates on BE:
splenectomy, diagnosis year (before 1991 or after 1991,
the year ERT became available), genotype (N370S/
N370S or others), age at diagnosis (before 15 or after 15
years old) and sex. The impact of each covariate on the
time to the first BE was tested using the log-rank test. A
Cox model, used to estimate hazard ratios (HR) and
95% confidence intervals (CI), was applied to patients
before and during ERT. Influence of age at treatment
onset on BE occurrence under ERT was tested with a
Cox model.
Fourth, the covariates were tested in mixed models.
These analyses were only applied to the patients under
ERT because of insufficient data on the patients before
ERT. Backward selection of the covariates entered into
the model was applied to examine associations between
a biomarker and the different covariates. For the before-
ERT and during-ERT analysis periods, individual base-
line and slope values estimated with the linear-mixed
models with no covariate for each patient and for each
biomarker were extracted. These values were entered
into a Cox model, to evaluate the relationship between
BE and biomarker changes using the PHREG procedure,
and are expressed as HR and 95% CI.
A biomarker effect on BE occurrence before ERT was
not analyzed because early information on biomarkers
was very sparse.
Results
Cohort
Seventy-three patients were followed, between 1933 and
1 May 2007, for a median duration of follow-up of 21
(range, 0 to 67) years after diagnosis. Only 62 patients
received ERT with a median total duration of follow-up
from diagnosis of 23.5 (range, 2 to 67) years and median
duration of follow-up under treatment of 6 (range, 0 to
15) years. Only these 62 patients were included in the
analysis.
The patients’ characteristics at diagnosis are reported
in Table 1. This mostly female cohort had a median
age of 14 years at diagnosis, but their first symptoms
had started at the median age of eight years. Bone-
marrow aspiration or biopsy led to GD diagnosis for
32 (51%) patients, and spleen histology was used for
13%. The diagnosis was confirmed for all patients by
determining glucocerebrosidase activity. Only one
patient died of GD-associated pulmonary hypertension
during follow-up.
All but four patients had phenotype 1 GD. Twenty-
eight patients had familial GD affecting siblings for
27 patients and an uncle for one patient. The genotype
Table 1 Description at diagnosis of the 62 Gaucher-
disease patients receiving enzyme-replacement therapy
Baseline characteristic Value
Sex, n (%)
Female 36 (58)
Male 26 (42)
Age, years, median (range)
First symptoms 8 (0 to 37)
Diagnosis 14 (1 to 48)
Patients diagnosed before 1991, n (%) 47 (76%)
Patients <15 years old at diagnosis, n (%) 34 (55%)
First symptoms to diagnosis interval, years, median (range) 1 (0 to 36)
Test leading to diagnosis, n (%)
Enzyme assay 7 (11)
Enzyme-gene sequencing 1 (2)
Myelogram 26 (42)
Bone-marrow biopsy 4 (6)
Bone biopsy 2 (3)
Hepatic biopsy 2 (3)
Spleen histology 8 (13)
Other 1(2)
Unknown 11 (18)
Phenotype, n (%)
1 58 (93)
3 4 (7)
Genotype, n (%)
N370S/N370S 9 (14)
N370S/L444P 12 (19)
Other 27 (44)
Unknown 14 (23)
Familial disorder, n (%)
Yes 28 (45)
No 23 (37)
Unknown 11 (18)
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nine N370S/N370S,1 2N370S/L444P and two L444P/
L444P.
The first ERT prescribed was alglucerase for 18 (29%)
patients and imiglucerase for 44 (71%); ERT was started
at a median of 14 (range, 0 to 61) years after diagnosis;
median age (range) at ERT onset was 31.6 (4.4 to 65.9)
years. The respective median ages (range) at treatment
onset for patient with and without BE were 29.5 (15.6 to
51.1) years and 32 (4.4 to 65.9) years. Cox analysis
results showed no influence of age at treatment onset
on BE occurrence during ERT (HR = 1.017 (95% CI:
0.975 to 1.061), P = 0.42). All patients taking alglucerase
were switched to imiglucerase in November 1996. For
alglucerase or imiglucerase, the initial dose was 120 U/
kg/month (full dose) for 55 patients, with lower doses
for the others: median 90 (range, 30 to 90) U/kg/month.
Four patients switched from imiglucerase to miglustat.
Twenty-eight of the 55 patients receiving full doses had
their doses lowered after a median of 2.9 (range, 0.1 to
12.2) years of ERT.
Table 2 shows clinical, biological and bone data at dif-
ferent times: diagnosis, ERT onset and closing date.
However, median times to ERT onset differed when GD
had been diagnosed before 1991 or after 1991 (respec-
tively 18 and 7 years; P < 0.05). Median ages at ERT
onset and the closing date were 33.3 and 39.8 years,
respectively.
During ERT, clinical abnormality rates decreased
(except for neurological involvement) and the biological
data improved overall during ERT (increased hemoglo-
bin, leukocyte and platelet levels; decreased chitotriosi-
d a s e ,A C E ,T R A P ,f e r r i t i na nd gammaglobulin levels).
The number of patients with splenomegaly and/or hepa-
tomegaly tended to decline during ERT, and most bone
lesions other than BE tended to regress (Table 2).
Overall, 21 (34%) patients were splenectomized: 5
before diagnosis, 16 between diagnosis and ERT onset;
none were splenectomized after starting ERT. The med-
ian age at splenectomy was 18.3 (range, 1.6 to 49.6)
years.
BE characteristics
Kaplan-Meier curves of the time to the first BE in the
62 treated patients, between diagnosis and ERT onset
(30 years of follow-up), and between the latter and the
closing date (15 years of follow-up) are shown in Fig-
ure 1a and 1b, respectively. Before diagnosis, eight
patients had already suffered at least one BE. After
diagnosis, but before starting ERT, 21 patients had had
at least one BE, for a total of 54 BE and a median of
two (range, 1 to 8) BE per patient. Ten patients had at
least one BE during ERT for a total of 12 BE. The 54
BE before ERT onset were (n (%)): 28 (52%) avascular
necroses (with 12 prosthetic replacements), 7 (13%)
bone infarcts (with only symptomatic therapy), 12
(22%) pathologic fractures (5 requiring surgical inter-
vention) and 7 (13%) vertebral compression fractures
(with symptomatic therapy). Moreover, 23 complaints
of bone pain were not corroborated by imaging (hence
not included in BE). The 12 BE that occurred under
ERT were (n (%)): three (25%) avascular necroses
(none with prosthetic replacement), four (33%) bone
infarcts with clinical bone crises (with only sympto-
matic therapy) and five (42%) pathological fractures
(none requiring surgery). Twenty-one complaints of
simple bone pain without imaging confirmation during
ERT were not included in BE. For nine of the 12 BE,
patients received full-dose ERT (120 U/kg/month).
Only one patient experienced BE during the first year
of ERT (pathological fracture), and 5 of the 10 patients
experienced BE between Years 1 and 5 of ERT (two
pathological fractures, one avascular necrosis and two
bone infarcts).
We determined the probability of a BE occurring by
10 years (95% CI) before and during ERT: 22.4% (13.3%
to 36.3%) and 20.0% (10.2% to 36.9%), respectively.
Respective mean times (95% CI) to the first BE were
27.6 (21.5 to 33.7) and 12.0 (10.7 to 13.3) years. For
four of the 21 (19.0%) patients with at least one BE
before ERT, the BE occurred before and during ERT,
whereas six of the remaining 41 (14.6%) patients devel-
oped BE only during ERT, but had never done so
before.
Biomarker evolution before and during ERT
Results of analyses of biomarker changes using linear-
mixed models are reported in Table 3. Platelet counts in
nonsplenectomized patients were stable before ERT
(+190 platelets/year), while chitotriosidase and TRAP
decreased slightly, and ferritin and ACE increased
slightly. During ERT, platelet counts increased (+7,035
platelets/year), while all other biomarkers declined.
Slopes before and during ERT differed significantly (P =
0.0001) only for platelets and ferritin. For patients given
full-dose ERT, platelet counts increased slightly faster,
ferritin and TRAP decreased faster, but chitotriosidase
and ACE declined more slowly. When only patients
with full-dose ERT were analyzed, their biomarker-slope
variations were comparable to those of the other
patients.
Impact of covariates and biomarkers on developing BE
Covariate (splenectomy, date of diagnosis, genotype, age
at diagnosis and sex) impact on BE before and during
ERT was examined. Before ERT, significantly more BE
occurred in patients diagnosed with GD after 15 years
o fa g e( H R ,2 . 6( 9 5 %C I ,1 . 0t o6 . 7 ) ;P = 0.048), but no
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ates, and none had an effect during ERT.
Estimated individual slopes of the biomarkers had no
significant influence on developing BE before or during
ERT but, at diagnosis, ferritin concentration (HR, 1.18
( 9 5 %C I ,1 . 0 3t o1 . 3 5 ) ;P = 0.019) and platelet count
(HR, 0.69 (95% CI, 0.49 to 0.98); P = 0.039) increased
the risk of BE during ERT in this univariate model. Risk
of BE increased with high ferritin levels and low platelet
levels.
For patients under ERT, a multivariate regression
model including age at diagnosis and ferritin and
Table 2 Clinical, biological and imaging characteristics of Gaucher disease precisely known at each time
Characteristic No. At diagnosis No. At ERT onset No. At closing date
Years since diagnosis, median (range) 0 14 (0 to 61) 23.5 (2 to 67)
Clinical involvement
Pigmentation 35 6% 35 20% 29 3%
Asthenia 45 42% 52 60% 53 26%
Abdominal pain 45 29% 50 34% 54 6%
Chronic bone pain 1 0% 52 58% 55 45%
Bone crisis 38 24% 45 49% 51 12%
Hemorrhage 44 52% 53 43% 53 9%
Lung 41 2% 49 0% 52 6%
Neurological 40 5% 45 7% 41 15%
Other 28 4% 32 6% 19 0%
Splenectomy, n 62 5 62 21 62 21
Organomegaly
Hepatomegaly 48 85% 47 89% 39 54%
Liver US (median, range), cm 23 16.5 (13 to 25) 28 19 (13 to 30) 9 14 (11.8 to 19)
Splenomegaly 40 100% 41 95% 30 67%
Splenic US (median, range), cm 34 18.75 (9.5 to 30) 26 19.4 (9.5 to 31.5) 11 15.2 (9 to 22)
Biological parameter, median (range)
Hemoglobin (g/dL) 15 11.4 (7.9 to 14.1) 55 12 (8.3 to 15.1) 58 13.8 (7.3 to 16.2)
Leukocyte (/mm
3) 15 4,300 (2,070 to 12,400) 54 4,200 (1,180 to 21,600) 57 6,130 (850 to 11,600)
Platelet count (×10
3/mm
3) 57 88 (6 to 380) 53 87 (30 to 449) 58 165.5 (37 to 473)
Chitotriosidase (nmol/mL/h)* 28 9,501 (70 to 77,500) 27 9,700 (180 to 77,500) 53 1123 (8 to 14,893)
TRAP (IU/L) 23 11 (1 to 47) 15 9.6 (1 to 24.5) 36 3.75 (2 to 48)
ACE (IU/L) 28 259.5 (1 to 650) 21 220 (1 to 650) 46 51 (0.9 to 240)
Ferritin (ng/L) 38 682.5 (68 to 3,230) 28 721.5 (120 to 3,230) 47 167 (15 to 1,731)
Gammaglobulin (g/L) 2 17.7 (16.5 to 19) 31 15.8 (7.2 to 25) 47 12.7 (6.5 to 23.6)
Imaging of bone disorders
Erlenmeyer flask 23 52% 22 64% 14 36%
Osteopenia 23 57% 18 56% 17 47%
Cortical 19 32% 13 23% 9 0
Lytic lesion 19 26% 14 21% 15 33%
Avascular necrosis sequelae 27 37% 17 29% 13 23%
Infarct sequelae 22 32% 15 40% 12 25%
Fracture sequelae 18 17% 11 0 11 27%
Infiltration on MRI 25 80% 33 91% 31 81%
99mTc-Hyperfixation 25 84% 29 90% 25 88%
99mTc-Hypofixation 4 50% 5 20% 3 0
Bone densitometry, median (range)
T-score neck 3 -2.1 (-2.2 to -1.1) 10 -1 (-2.2 to 1.4) 22 0 (-2.8 to 4.5)
T-score lumbar 13 0 (-3.1 to 1) 10 -1.9 (-4 to 0.8) 22 -0.9 (-3.6 to 1.6)
Z-score neck 7 8 (-2.03 to 8) 7 -0.7 (-2 to 1.9) 15 -0.3 (-2.6 to 4.4)
Z-score lumbar 2 -2.4 (-3.1 to -1.8) 8 -1.3 (-3.1 to 0.5) 15 -0.5 (-3 to 2.1)
No. is the number of patients with available information. ACE, angiotensin-converting enzyme; ERT, enzyme-replacement therapy; MRI, magnetic resonance
imaging; TRAP, tartrate-resistant acid phosphatase; US, ultrasonography. *In addition, four patients had undetectable chitotriosidase activity (null allele) and are
not included for statistical analysis of chitotriosidase.
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(P = 0.032) to have a significant impact.
Influence of covariates on biomarker changes during ERT
Table 4 reports the effects of covariates on biomarker
values during ERT, including the coefficients of variation
of interindividual variability for baseline levels and
slopes for each biomarker. These coefficients were parti-
cularly high for the platelet count, ferritin and ACE
slopes. However, only the ferritin and platelet slopes dif-
fered significantly between before and during ERT
(Table 3).
Figure 1 Time until the first bone event (BE) in the 62 Gaucher-disease patients receiving enzyme-replacement therapy (ERT).T h e
dashed grey lines represent the 95% CI of the survival curve. (a) Between diagnosis and first ERT during the first 30 years of follow-up. (b)
Between first ERT and closing date (for treated patients) during 15 years of follow-up. No. at risk is the number of patient followed at the
indicated time; No. with BE is the number of patients who had a BE. Twenty-one patients had BE before ERT and 10 under ERT during each
follow-up period.
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marker changes under ERT. Figure 2a shows the influ-
ence of splenectomy on the platelet change. Values at
diagnosis and progression slopes differed between sple-
nectomized and nonsplenectomized groups. Splenecto-
mized patients’ platelet counts rose slightly under ERT,
with no significant slope change, while nonsplenecto-
mized patients’ counts increased significantly from base-
line under ERT but returned to normal after 6.5 years
of treatment. Two covariates affected the chitotriosidase
decrease under ERT: splenectomy influenced the slope
decline and genotype influenced the baseline level (Fig-
ure 2b). Patients with the genotype N370S/N370S had
significantly higher baseline levels, which decreased
more steeply than those of patients with another geno-
type. This impact could reflect the fact that, patients
with that genotype, which corresponds to one of the
less severe forms of GD, started ERT later (median, 23
years) than the other patients (median, 16 years) (nonsi-
ginficant, NS). Chitotriosidase levels decreased, without
reaching a normal level over a median of six (range, 0
to 15) years of follow-up.
The ferritin model did not identify any covariate as
significantly influencing this marker’s progression (Fig-
ure 2c). The mean prediction curve for ferritin levels
decreased and became the normal after three years.
Table 3 Changes of the slopes* of the Gaucher-disease biomarkers
Slope of variation (Unit) P
a
Biomarker No./no. Before ERT No./no. During ERT No./no. Full-dose ERT
Platelets (no splenectomy)
b 9/70 190/mm
3/y 38/480 7,035/mm
3/y 33/220 10,231/mm
3/y <0.0001
Chitotriosidase 10/23 -11%/y 52/226 -17%/y 37/134 -14%/y 0.14
TRAP 7/14 -0.7%/y 36/214 -4%/y 24/109 -6%/y 0.78
ACE 9/33 0.1%/y 46/263 -5%/y 31/114 -4%/y 0.88
Ferritin 9/45 4%/y 47/338 -14%/y 37/166 -16%/y <0.0001
*Slopes were estimated by linear-mixed models before enzyme-replacement therapy (ERT), during ERT and for the patient subgroup receiving full-dose ERT.
aComparison of slope values before vs during ERT.
bOnly for nonsplenectomized patients. No./no. indicates number of patients with available data/total number
of data available. ACE, angiotensin-converting enzyme; TRAP, tartrate-resistant acid phosphatase.
Table 4 Baseline levels and slope changes* of the biomarkers during enzyme-replacement therapy: impact of
covariates
Biomarker Covariate(s) N Baseline P CV
a Slope of % decrease
b P CV
a
Platelets
No splenectomy 38 108,850 (/mm
3) 56.5% 7 035 (/mm
3/yr) 80.7%
Splenectomy 20 309,380 (/mm
3) -882 (/mm
3/yr)
Effect of splenectomy <0.0001 0.0007
Chitotriosidase ND
No splenectomy-N370S 6 14,721 nmol/mL/h 9.8% -38% (/yr)
No splenectomy-other genotype 22 3,581 nmol/mL/h -14% (/yr)
Splenectomy-N370S 2 8,283 nmol/mL/h -27% (/yr)
Splenectomy-other genotype 11 2,015 nmol/mL/h -2% (/yr)
Effect of splenectomy 0.19 0.015
Effect of genotype 0.006 0.018
Ferritin 47 382 ng/L 15.4% -14% (/yr) 83.6%
ACE
Diagnosis before 1991 35 90.3 (IU/L) 25.5% -7% (/yr) 190.1%
Diagnosis in 1991 and after 11 31.7 (IU/L) 4% (/yr)
Effect of diagnosis data 0.020 0.055
TRAP
No splenectomy-diagnosis >15 yr 10 4.2 (IU/L) 3.6% -4% (/yr) ND
No splenectomy-diagnosis 15 yr 13 6.6 (IU/L) -9% (/yr)
Splenectomy-diagnosis >15 yr 5 3.5 (IU/L) 3% (/yr)
Splenectomy-diagnosis <15 yr 8 5.4 (IU/L) -2% (/yr)
Effect of splenectomy 0.32 0.004
Effect of age at diagnosis 0.016 0.057
*Estimated with linear-mixed models under treatment.
aCoefficient of variation of interpatient variability.
bWhen a log-linear model was used, the evolution is
expressed as the percent change of the slope (all markers except platelets). ND, not determined.
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levels (Figure 2d). Patients diagnosed before 1991 had
much higher ACE levels (90.3 versus 31.7 U/L), but
their progression slopes did not differ significantly.
Splenectomy and age at diagnosis affected TRAP
levels, with the former influencing the decrease rate
(slope) and the latter the baseline concentration (Figure
2e). TRAP levels in splenectomized patients decreased
more slowly and had started higher, but the difference
was not significant. Patients diagnosed before the age of
15 years had the highest baseline TRAP levels but their
diagnosis-to-ERT interval was 17 years, as opposed to
Figure 2 Biomarker changes under enzyme-replacement therapy (ERT): impact of covariates. (a) platelet level, (b) chitotriosidase, (c)
ferritin, (d) angiotensin-converting enzyme (ACE), and (e) tartrate-resistant acid phosphatase (TRAP). Different covariates were tested to identify
those impacting on biomarker evolution (baseline or variation slope): splenectomy, diagnosis year (before 1991 or after 1991, the year ERT
became available), genotype (N370S/N370S or others), age at diagnosis (before 15 or after 15 years old) and sex. Solid grey horizontal lines
correspond to the normal biomarker value: platelet level >150,000/mm
3; chitotriosidase <100 nmol/mL/h; ferritin <250 ng/L; ACE <45 IU/L; TRAP
<7 IU/L. When a covariate had a significant impact on the baseline value or the variation slope, the different curves are shown.
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Although that difference was not significant, more sub-
strate could have accumulated in the patients who were
diagnosed before the age of 15, because their time pre-
ceding ERT onset had been much longer.
Splenectomy eliminates platelet anomalies and dis-
places lysosomal overload. Nonsplenectomized patients
seemed to have higher, but not significantly different,
lysosomal biomarker levels at diagnosis compared to
splenectomized patients, respectively: chitotriosidase
19,219 versus 2,534 nmol/mL/h (NS); TRAP 12.1 versus
8.0 (NS). In contrast, macrophage-biomarker levels were
higher in splenectomized than nonsplenectomized
patients, respectively: ferritin 1,301 versus 634 ng/L (P =
0.06); ACE 251 versus 202 IU/L (NS). Generally, for
splenectomized patients, when the starting value was
lower, the slope was less steep.
Some covariates were significantly associated: patients
diagnosed before 1991 were more often male (P =0 . 0 4 )
and had more frequently been splenectomized (P =
0.03).
Discussion
Probability curves of time to BE (Figure 1) before and
during ERT for GD patients showed that bone compli-
cations could occur without but also under ERT (about
20% at 10 years). According to the literature, bone crises
almost disappeared after two years of ERT [8,30], but
the risk of avascular necrosis was estimated to be 13.8/
1,000 person-years under ERT in a recent publication
[31]. Our findings demonstrated that BE can arise even
after many years of ERT, specifically avascular necrosis
(three patients) and bone infarcts (four patients). How-
ever, no patient had prosthetic replacement after ERT
compared to 12 before. BE after ERT seemed to be less
serious, as no surgery was required. In addition, simple
bone pain occurring under ERT without being con-
firmed by imaging (21 events) was not considered a BE.
Hence, ERT does not eliminate all bone symptoms.
Nine BE were documented under full-dose ERT (120 U/
kg/month of alglucerase or imiglucerase). We tried to
determine the impact of diagnosis year (before or after
1991) on BE occurrence and biomarker evolution: no
effect was found on BE occurrence (P = 0.11 and 0.42,
respectively, for before and after ERT). Although this
covariate significantly affected only baseline ACE levels
(see Figure 2d), it had no influence on the other biomar-
kers, for example, platelets and ferritin. No impact of
the date of diagnosis on baseline ferritin value or plate-
let count was found, as shown in Figure 2a, c and in
Table 4.
We hypothesize that bone infiltration accumulating
over the years before starting ERT could explain bone
complications despite treatment. Unfortunately, our
analysis does not allow us to confirm or refute that pos-
tulate. In a recent article, the risk of avascular necrosis
while on ERT seemed lower for patients who had begun
treatment within two years of diagnosis compared to
those who started it after more than and equal to two
years [31]. Moreover, patients were certainly more clo-
sely monitored during than before ERT and it is possible
that some BE before ERT might not have been diag-
nosed. A largest study with systematic bone-density data
will be considered to compare the bone densitometries
of patients with pathological fractures versus those of
patients without such fractures during evolution.
Because the platelet level did not rise in splenecto-
mized patients on ERT, it can be concluded that hypers-
plenism is the main cause of thrombopenia. However,
14 (61%) out of 21 splenectomized patients, had at least
one platelet count <150,000/mm
3 after splenectomy.
Therefore, bone-marrow insufficiency seems to explain
part of the thrombopenia observed over time.
The effect of individual estimated-biomarker values at
diagnosis or their slope on BE occurrence under ERT
was significant for baseline platelet and ferritin levels in
our univariate model, with high ferritin and low platelets
at ERT onset being significantly associated with BE dur-
ing ERT, but only the baseline platelet count was
retained in a multivariate model. Nor did the estimated
individual slopes of the biomarkers have a significant
impact on BE. However, our modeling method seemed
to be able to identify predictive biomarkers. Effects of
others biomarkers was not significant in our analyses
but platelet and ferritin data were available for more
patients at diagnosis (57 and 38, respectively) compared
to the others (28, 23 and 28, for chitotriosidase, TRAP
and ACE, respectively), which could have decreased the
power of statistical analysis and partially explain these
observations. According to the literature, no biomarkers
were able to predict BE occurrence and, other than pla-
telets, ferritin seemed to be the only biomarker affecting
BE [19]. The only study using a mixed model for GD
[26] found dose-response relationships for ERT, but had
not considered biomarkers (chitotriosidase, TRAP, ferri-
tin, ACE), taking into account only the main hematolo-
gical (hemoglobin and platelets) and visceral
manifestations; no prediction of BE occurrence was
proposed.
Interpatient biomarker changes and therapeutic
responses varied widely (Table 3). TRAP baseline was
higher for the group diagnosed before 15 years than
those diagnosed later, which seems to support that the
TRAP level could differ as a function of age [32]. The
respective median ages for the groups of patients diag-
nosed before and after 15 years were 21 and 40 years,
which partially explains these findings. The ACE level
was affected by the year of diagnosis, with patients
Stirnemann et al. Arthritis Research & Therapy 2010, 12:R156
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Page 9 of 11diagnosed after 1991 having lower baseline levels than
those diagnosed before 1991. ERT availability since 1991
could have limited the ACE rise. For some biomarkers,
not all patients had the same evolution under ERT: for
example, platelet counts rose in 97% of treated patients,
while chitotriosidase decreased in 100% and ferritin in
96%, but ACE levels in only 78%.
Conclusions
BE can occur in GD even after many years of ERT.
Initial ferritin and platelet levels seemed to be able to
predict BE occurrence during ERT. To achieve our final
objective, to predict BE based on initial biomarker
values and their evolution, large cohort studies are
needed.
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